Currrax Pharmaceuticals over-performed its 2024 revenue goal and has exceeded 50% year-over-year revenue growth for its ...

West Pharma’s financial strength is solid, and the firm has historically managed a very strong balance sheet. As of year-end 2023, West had total debt outstanding of $206 million. West has ...

Ormat Technologies has secured two 15-year tolling agreements for energy storage facilities in Israel in a significant entry ...

Professor Timothy Yang, associate professor and director of the Center for Asian Studies at the University of Georgia, ...

Stock analysts noted Natco Pharma’s missed consensus Q3 estimates on both revenue and Ebitda margin fronts due to lack of ...

Vanda Pharmaceuticals sees strong growth with Fanapt for bipolar I disorder, projects 2025 revenue up 6%-26%, and targets $1B by 2030.

For the psychiatry portfolio alone, Vanda is targeting annual revenue in excess of $750M in 2030, assuming the potential approval of Bysanti ...

According to Statifacts, the global clinical trials market size is calculated at USD 126.30 billion in 2025 and is expected to reach around USD 186.09 billion by 2034, growing at a CAGR of 4.4% from ...

Valuation discrepancies in the biotech sector highlight Shuttle Pharma’s incredible potential. With several peer companies in ...

ReElement Technologies entered into a partnership with Novare to develop integrated refining facilities across Africa with ...

Google is reevaluating its DEI initiatives, ending hiring targets, and reviewing diversity programs amid policy shifts ...

The ingredients in fentanyl are largely produced by companies in China and used by pharmaceutical companies to make legal ...